Notice2023-05715
CDC Recommendations for Hepatitis B Screening and Testing-United States, 2022
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 21, 2023
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the availability of the final CDC Recommendations for Hepatitis B Screening and Testing--United States, 2022.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 54 (Tuesday, March 21, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 54 (Tuesday, March 21, 2023)]
[Notices]
[Page 16981]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-05715]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0044]
CDC Recommendations for Hepatitis B Screening and Testing--United
States, 2022
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: General notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), within
the Department of Health and Human Services (HHS), announces the
availability of the final CDC Recommendations for Hepatitis B Screening
and Testing--United States, 2022.
DATES: The final document was published as an MMWR Reports &
Recommendations on March 10, 2023.
ADDRESSES: The document may be found in the docket at
<a href="http://www.regulations.gov">www.regulations.gov</a>, Docket No. CDC-2022-0044 and at <a href="https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w">https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w</a>.
FOR FURTHER INFORMATION CONTACT: Erin Conners, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop U12-3, Atlanta,
GA 30329. Telephone: 404-639-8000; Email: <a href="/cdn-cgi/l/email-protection#9fdbc9d7eff0f3f6fce6dffcfbfcb1f8f0e9"><span class="__cf_email__" data-cfemail="db9f8d93abb4b7b2b8a29bb8bfb8f5bcb4ad">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In 2022, CDC determined that CDC
Recommendations for Hepatitis B Screening and Testing--United States,
2022 constituted influential scientific information (ISI) that will
have a clear and substantial impact on important public policies and
private sector decisions. Under the Information Quality Act, Public Law
106-554, federal agencies are required to conduct peer review of the
information by specialists in the field who were not involved in the
development of these recommendations. CDC solicited nominations for
reviewers from the American Association for the Study of Liver Diseases
(AASLD), Infectious Diseases Society of America (IDSA) and American
College of Physicians (ACP). Five clinicians with expertise in
hepatology, gastroenterology, internal medicine, infectious diseases,
and/or pediatrics provided structured peer reviews. A list of peer
reviewers and CDC's responses to peer review comments are available at
CDC's Viral Hepatitis Influential Scientific Information web page at
<a href="https://www.cdc.gov/hepatitis/policy/isireview/index.htm">https://www.cdc.gov/hepatitis/policy/isireview/index.htm</a>.
In addition, on April 4, 2022, CDC published a notice in the
Federal Register (87 FR 19516-19517) to obtain public comment on the
draft recommendations for hepatitis B screening and testing. The
comment period closed on June 3, 2022. CDC received comments from 28
commenters on the draft recommendations document. Public commenters
included those from academia, the health care sector, advocacy groups,
professional organizations, industry, the public, and a consulting
group.
Many of the comments expressed support for the recommendations.
Other comments related to the 3-panel test recommendation, inclusion of
hepatitis D information, the hepatitis B prevalence estimate, modifying
testing and vaccination language, adding scientific references, and
making other minor language modifications. CDC addressed these comments
by correcting, clarifying, or updating content in the final
recommendations. A summary of public comments and CDC's response can be
found in the Documents tab of the docket.
Tiffany Brown,
Acting Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2023-05715 Filed 3-20-23; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 21, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.